The energy company takes a hit after earnings, but there's still reason for optimism.
The portfolio has outperformed the Russell 2000 index by more than 400 basis points, year to date.
Just five non-biotech names trade below net current asset value.
Small biotech tanked on weak earnings, but still seems promising.
I expect Allergan or another player to bid for SGYP soon.
These have positive momentum and good growth.
The continued growth in housing starts is a good sign for homebuilders in the new year, says Stocks Under $10 Portfolio Manager David Peltier.
Higher interest rates should boost earnings growth for regional banks, says Portfolio Manager David Peltier.
This homebuilder appears oversold, but Portfolio Manager David Peltier likes its exposure to California.
Low-dollar retail stocks are reaching new highs. Portfolio Manager David Peltier handicaps the sector.